Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported a net loss of $78.5 million for fiscal year 2025, driven by significant operating expenses of $85.3 million, primarily from research and development ($70.1 million) and general and administrative costs ($15.2 million). The company generated no revenue during the period, resulting in an operating loss of $85.3 million. This was partially offset by other income of $6.8 million, mainly from interest and investment income ($5.5 million). The company's cash position improved by $11.3 million to $14.4 million, supported by $77.4 million in net proceeds from equity financing. With total assets of $168.2 million and stockholders' equity of $147.5 million, the company maintains a strong liquidity position despite ongoing operational losses.

Key Takeaways